French pharma major Sanofi (Euronext: SAN) has received marketing authorization in Europe for its diabetes therapy Suliqua, known as Soliqua (insulin glargine and lixisenatide combination) in the USA.
The decision enables Sanofi to start commercializing the drug in all 28 member states of the European Union, as well as Iceland, Liechtenstein and Norway. The company intends to begin launching in individual countries in the second quarter of 2017.
The product was approved by the US Food and Drug Administration in November 2016, and has been available there since the start of this year for the treatment of adults with type 2 diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze